Press releases

Company anticipates broad range of clinical results on endoscopic technologies

Single-operator system allows unprecedented visual access to bile duct

Company to release broad range of clinical data on leading drug-eluting stent portfolio

More than 23,000 patients now enrolled in TAXUS OLYMPIA registry

New data provide support for minimally invasive treatment of atrial fibrillation (AF)

Data represents the industry's largest experience with wireless remote monitoring of implantable cardiac devices for one year

Reimbursement granted by National Health Insurance System

RENAISSANCE trial demonstrates durable results for Company's Express® SD Renal Stent in treating hypertensive patients with severe renal artery stenosis

Sam Leno will join the Company as Chief Financial Officer (CFO) and Executive Vice President of Finance and Information Systems

SYNTAX is the first trial to compare the results of drug-eluting stents with those of cardiac surgery in the most complex patient subsets

A live webcast and replay of the May 2 conference session will be available

"I am pleased we came in at the upper end of our ranges for sales and EPS for the quarter," said Jim Tobin, President and Chief Executive Officer

Product provides enhanced control for accessing desired vessel location

A live webcast and replay of the April 23 conference call will be available.

Company has resolved deficiencies in the warning letter issued by the U.S. Food and Drug Administration (FDA) to the Guidant Corporation

Company plans to launch the product after reimbursement approval is granted

Trial is designed to identify and investigate clinically relevant endpoints for evaluating the efficacy and durability of endovascular treatment of brain aneurysms

BTK CHILL study demonstrates high rate of limb protection at one year

TAXUS® Express2™ paclitaxel-eluting coronary stent system met its primary endpoint in the treatment of in-stent restenosis

Two-year review of TAXUS Stent safety data presented at ACC

Results reaffirm strength of Boston Scientific's dual drug-eluting stent program

Compliance program is the first of its kind in the medical device industry; is expected to launch in the United States later this year

Smallest Dual Chamber System offered in Japan provides enhanced therapies to patients at risk of sudden cardiac death

Company to host analyst meeting and symposium on drug-eluting stents

A live webcast and replay of the March 19 conference session will be available

IPO would involve Boston Scientific selling approximately 20 percent of the Endosurgery group and establishing a separately traded public company

Boston Scientific Corporation (NYSE: BSX) today announced several enhancements related to the governance of the company. "Boston Scientific is...

A live webcast and replay of the March 13 conference session will be available

Company looks forward to providing the Committee the information it has requested relating to TAXUS® paclitaxel-eluting coronary stents

Campaign spokesperson - a Formula race car driver, amputee, and chronic pain patient - to promote public awareness

Swedish registry further illustrates the strengths and weaknesses of so-called "real-world" registries when compared to prospective, randomized and actively controlled trials

Articles scheduled for publication in the March 8th edition confirm the safety and efficacy of TAXUS® Express2™ paclitaxel-eluting coronary stent system

DES patients have significantly lower rates of death, heart attack and re-intervention than BMS patients

Company supports the proposed expansion but also supports broader coverage

Company provides guidance for first quarter 2007December 31, 2006, as well as...

Company will webcast its conference call discussing financial results for the fourth quarter and the year ended December 31, 2006 on Thursday, February 1, at 8:30 a.m.

Boston Scientific Corporation (NYSE: BSX) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to expand its...

The live webcast and archived replay of the Thursday, February 1 call will be available

New U.S. shelf life is longer than any competing drug-eluting stent product

Court orders injunction and damages

U.K. Court of Appeal affirmed an earlier ruling to revoke the U.K. version of a European paclitaxel stent patent owned by Angiotech Pharmaceuticals, Inc.

Lower rates of re-intervention and major adverse events reported for the TAXUS Stent in study of diabetic patients

Boston Scientific only company to offer two distinct drug-eluting stent platforms

Boston Scientific Corporation (NYSE: BSX) today announced preliminary, unaudited net sales for its fourth quarter and full year ended December 31,...

Plan to increase innovation, productivity and competitiveness

Acquisition demonstrates Company's commitment to leadership in treating carotid artery disease

A live webcast and replay of the Tuesday, January 9th session will be available

Trial highlights the importance of appropriate pacing for patients at risk of sudden cardiac death